Edition:
United States

G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

34.11USD
12 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$34.11
Open
$34.50
Day's High
$35.00
Day's Low
$33.65
Volume
123,917
Avg. Vol
122,655
52-wk High
$69.23
52-wk Low
$18.45

Latest Key Developments (Source: Significant Developments)

Preliminary Results From Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival In Combination With Chemotherapy In Patients With Metastatic Triple-Negative Breast C
Tuesday, 4 Dec 2018 06:55am EST 

Dec 4 (Reuters) - G1 Therapeutics Inc ::PRELIMINARY RESULTS FROM RANDOMIZED PHASE 2 TRIAL DEMONSTRATE TRILACICLIB IMPROVED PROGRESSION-FREE SURVIVAL IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER.G1 THERAPEUTICS INC - PATIENTS ON TRILACICLIB RECEIVED MORE CHEMOTHERAPY CYCLES THAN THOSE IN CONTROL ARM.G1 THERAPEUTICS INC - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED TRIALS; NO TRILACICLIB-RELATED SERIOUS ADVERSE EVENTS REPORTED.G1 THERAPEUTICS INC - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED TRIALS; NO TRILACICLIB-RELATED SERIOUS ADVERSE EVENTS REPORTED.G1 THERAPEUTICS INC - NO TRILACICLIB-RELATED SERIOUS ADVERSE EVENTS REPORTED.G1 THERAPEUTICS INC - ON A PER-PATIENT BASIS, NUMBER OF PATIENTS EXPERIENCING MYELOSUPPRESSION EVENTS WAS SIMILAR ACROSS THREE ARMS.  Full Article

G1 Therapeutics Inc QTRLY Loss Per Share $0.59
Wednesday, 7 Nov 2018 04:01pm EST 

G1 Therapeutics Inc ::G1 THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE.G1 THERAPEUTICS INC - PRELIMINARY DATA FROM THREE ADDITIONAL RANDOMIZED PHASE 2 CLINICAL TRIALS OF TRILACICLIB EXPECTED BY END OF 2018.G1 THERAPEUTICS INC QTRLY LOSS PER SHARE $0.59.G1 THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $390.5 MILLION AS OF SEPTEMBER 30, 2018.  Full Article

G1 Therapeutics qtrly ‍loss per share $0.55
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - G1 Therapeutics Inc ::G1 therapeutics reports third quarter 2017 financial results and recent operational highlights.G1 therapeutics inc - qtrly ‍loss per share $0.55.G1 therapeutics inc - qtrly loss per share ‍$0.55​.Q3 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.G1 therapeutics inc- ‍cash, cash equivalents and short-term investments totaled $118.4 million as of sept 30, 2017, versus $47.3 million as of dec 31, 2016​.  Full Article

G1 Therapeutics Inc appoints Barclay (Buck) Phillips as CFO and SVP, corporate development​
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - G1 Therapeutics Inc ::G1 Therapeutics Inc - appoints barclay (buck) phillips as chief financial officer and senior vice president, corporate development​.G1 Therapeutics Inc - ‍G1 announced that chief business officer Greg Mossinghoff will depart company in January of 2018​.  Full Article